An in vitro investigation of CD70-targeting CAR T-cells found that the administration of the modified T-cells resulted in T-cell activation, CD27 co-stimulation, and recognition and killing of CD70-positive tumor cell lines and primary tumor samples [75]. Here, CD27 is linked to neoplasm.